[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352022-105":59,"doc-detail-352022-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","implementation-and-evaluation-of-an-ambulatory-care-pathway-for-intra-arterial-treatment-of-primary-liver-cancer-study-protocol-for-a-multicentre-randomised-controlled-hybrid-type-1-trial-choc","Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC)","","Primary liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, remain major causes of cancer-related death. Transarterial chemoembolisation and radioembolisation are established palliative options but are usually delivered during inpatient stays. The CHOC trial evaluates whether an ambulatory care pathway for intra-arterial treatment aligns with patient expectations and clinical priorities. This pragmatic multicentre hybrid type 1 randomised trial compares ambulatory versus conventional inpatient care for TACE or TARE.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/implementation-and-evaluation-of-an-ambulatory-care-pathway-for-intra-arterial-treatment-of-primary-liver-cancer-study-protocol-for-a-multicentre-randomised-controlled-hybrid-type-1-trial-choc/352022/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/implementation-and-evaluation-of-an-ambulatory-care-pathway-for-intra-arterial-treatment-of-primary-liver-cancer-study-protocol-for-a-multicentre-randomised-controlled-hybrid-type-1-trial-choc/352022.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main objective of the CHOC trial?","Question",{"text":113,"@type":114},"To evaluate the implementation and effectiveness of an ambulatory care pathway for intra-arterial treatment of primary liver cancer from both patient-centred and clinical perspectives.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the study compare ambulatory care with conventional care?",{"text":118,"@type":114},"It is a multicentre randomised controlled hybrid type 1 trial comparing ambulatory versus conventional inpatient care for patients undergoing TACE or TARE.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the primary outcome and how is it measured?",{"text":122,"@type":114},"The primary outcome is global patient satisfaction, measured 3 days after the procedure using the EORTC PATSAT-C33 questionnaire.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352022,1790173891,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Open access Protocol  \n Implementation and evaluation of an  \nambulatory care pathway for intraarterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC)  \nJules Grégory  ,1 Jean-François Hammel,2 Maxime Ronot,1 Charles Roux,3 Maxime Barat,4 Manon Allaire,5 Lucia Parlati,6 Nadia Moussa,7 Paul Beunon,8 Frédéric Oberti,9 Patrick Chevallier,10 Rodolphe Anty,11 Paul Girot,12 Olivier Sutter,13  \nNathalie Ganne,14 Panteleimon Papadopoulos,15 Jean-Frédéric Blanc,16 Julien Ghelfi,17 Thomas Decaens,18 Thierry Yzet,19 Eric Nguyen-Khac,20 Benoît Magnin,21 Léon Muti,22 Jean-Romain Risson,23 Florence Tann,24 Valérie Boige,25 Paul Calame,26 Carine Richou,27 Valérie Vilgrain,1  \nPierre-Emmanuel Rautou,28 Astrid Darsonval,29 Rita Nhora,30 Julie Devictor,30 Mohamed Bouattour,31 Emmanuelle Cartron,30 Christophe Aubé32  \nTo cite: Grégory J, Hammel J-F, Ronot M, et al. Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC) . BMJ Open 2026;16:e114720 . doi:10 . 1136/ bmjopen-2025-114720  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2025-114720](bmjopen-2025-114720)) .  \nReceived 30 November 2025 Accepted 22 July 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Jules Grégory; [jules.gregory@aphp.fr](jules.gregory@aphp.fr)  \nABSTRACT  \nIntroduction Primary liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, are one of the leading causes of cancer-related mortality. Transarterial chemoembolisation (TACE) and radioembolisation (TARE) are established palliative treatments yet they are traditionally performed during inpatient hospitalisation. Recent technical and organisational advances allow for safe same-day ambulatory procedures. In particular, the extent to which ambulatory intra-arterial therapy aligns with patients’expectations, comfort and quality of life remains poorly documented. The Care pathway for Hepatic intra-arterial Oncology in an ambulatory Context study (CHOC) trial aims to evaluate the implementation and effectiveness from both patient-centred and clinical perspectives of an ambulatory care pathway for intra-arterial treatment of primary liver cancer in a multicentre randomised hybrid type 1 trial. Methods and analysis CHOC is a pragmatic, multicentre, randomised controlled hybrid type 1 trial comparing ambulatory versus conventional inpatient care for patients undergoing TACE or TARE for primary liver cancer. A total of 206 patients (103 per arm) will be randomised 1:1 and followed for 7 months. The primary outcome is the patient’s global satisfaction score, measured 3 days postprocedure using the EORTC PATSAT-C33 questionnaire. Secondary outcomes include quality of life, safety, clinical outcomes, cost analysis and an embedded qualitative implementation study assessing acceptability, adoption, feasibility and sustainability across centres. Economic analyses will estimate both per-patient costs and the 5-year budget impact for the French national health insurance.  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ First multicentre randomised hybrid trial evaluating ambulatory intra-arterial treatment of liver cancer.  \n⇒ Integrates quantitative and qualitative methodologies to assess both effectiveness and real-world implementation.  \n⇒ Strong patient-centred design measuring satisfaction and quality of life using validated EORTC tools.  \n⇒ Includes a full medico-economic analysis (cost analysis and budget impact analysis), pro","cbCaikv1jrTopwcs","https://ap.wps.com/l/cbCaikv1jrTopwcs","pdf",258029,"English","# ABSTRACT\n## Introduction\n## Methods and analysis\n## Strengths and limitations of this study\n## Ethics and dissemination\n# INTRODUCTION","[{\"question\":\"What is the main objective of the CHOC trial?\",\"answer\":\"To evaluate the implementation and effectiveness of an ambulatory care pathway for intra-arterial treatment of primary liver cancer from both patient-centred and clinical perspectives.\"},{\"question\":\"How does the study compare ambulatory care with conventional care?\",\"answer\":\"It is a multicentre randomised controlled hybrid type 1 trial comparing ambulatory versus conventional inpatient care for patients undergoing TACE or TARE.\"},{\"question\":\"What is the primary outcome and how is it measured?\",\"answer\":\"The primary outcome is global patient satisfaction, measured 3 days after the procedure using the EORTC PATSAT-C33 questionnaire.\"}]","Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC) | PDF",1790097213,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f650be48e0435cdd2449f304815b6d2c.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdeb35dfdf5224e9209fb91e4c1b99c4.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bab75d709bd95d65b69224d718f70e3e.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc07b93dedc355db429e97c38dff57e4.webp",980,1306]